Phase IV data strengthen case for Toviaz in competitive overactive bladder market
This article was originally published in Scrip
Executive Summary
Pfizer has unveiled Phase IV results for its two overactive bladder (OAB) drugs at a time when new competitors are threatening the dominance of antimuscarinic agents, which are the current standard of care.